Melasa and Post-inflammatory hyperpigmentation after phototherapy
Conditions
Interventions
Melasma 4mg/ml group:A trace intradermal injection of 4mg/ml tranexamic acid was given to the lesion area on half of the face. Once every two weeks for a total of four sessions
Melasma 50mg/ml group:A trace intradermal injection of 50mg/ml tranexamic acid was given to the lesion area on half of the face. Once every two weeks for a total of four sessions
PIH 4mg/ml group:A trace intradermal injection of 4mg/ml tranexamic acid was given to the lesion area on half of the face. Once every two weeks for a total of four sessions
PIH 50mg/ml group:A trace intradermal injection of 50mg/ml tranexamic acid was given to the lesion area on half of the face. Once every two weeks for a total of four sessions
Sponsors
Plastic Surgery Hospital, Chinese Academy of Medical Sciences
Eligibility
Sex/Gender
All
Age
25 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria for the melasma group: 1. Adult patients aged 25–60 years with bilaterally symmetrical melasma. 2. Patients willing to receive intradermal tranexamic acid injections for facial melasma improvement and who voluntarily provide written informed consent. 3. Not concurrently participating in any other clinical trial. Inclusion criteria for the PIH group: 1. Adult patients aged 25–60 years with at least one lesion of post-inflammatory hyperpigmentation (PIH) on each side of the face, resulting from prior light- or energy-based treatments, and with PIH duration exceeding 3 months. 2. Patients willing to receive intradermal tranexamic acid injections for facial PIH improvement and who voluntarily provide written informed consent. 3. Not concurrently participating in any other clinical trial.
Exclusion criteria
Exclusion criteria: Exclusion criteria for the melasma group: 1. Allergy to tranexamic acid or presence of contraindications to its use. 2. Severe infection, skin lesions, or scarring in the treatment area, rendering local injection unsuitable. 3. Coexisting severe systemic diseases, such as endocrine disorders, skin tumors, or immune/coagulation dysfunction. 4. History of laser therapy, chemical peeling, or use of pigment-inhibiting agents (topical or oral) in the melasma-affected area within the past 3 months. 5. Pregnant or lactating women. Exclusion criteria for the PIH group: 1. Allergy to tranexamic acid or presence of contraindications to its use. 2. Severe infection, skin lesions, or scarring in the treatment area, rendering local injection unsuitable. 3. Coexisting severe systemic diseases, such as endocrine disorders, skin tumors, or immune/coagulation dysfunction. 4. Use of hydroquinone, retinoid analogs, or other depigmenting agents within 4 weeks prior to enrollment; or any procedural treatments (e.g., laser therapy, chemical peels) performed within the past 6 months. 5. Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hemi-melasma area and severity index;Individual type Angle;Light Index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical efficacy;Patient satisfaction; | — |
Countries
China
Contacts
Public ContactHuang Lvping
Plastic Surgery Hospital, Chinese Academy of Medical Sciences
Outcome results
None listed